Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immunodeficiency Diseases

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency disorders...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Development of Immunocompetence

Development of Immunocompetence

The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

Primary Lymphoid Organs

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Attitudes of mothers to male circumcision in North-East Democratic Republic of Congo: A cross-sectional study.

African journal of reproductive health·2026

Same author

Experience of a systematic approach to care and prevention of fragility fractures in New Zealand.

Archives of osteoporosis·2022

Same author

Expanding Clinical Phenotype and Novel Insights into the Pathogenesis of ICOS Deficiency.

Journal of clinical immunology·2019

Same author

Secondary antibody deficiency - causes and approach to diagnosis.

Clinical medicine (London, England)·2016

Same author

General anesthesia suppresses normal heart rate variability in humans.

Chaos (Woodbury, N.Y.)·2014

Same author

Scalable technology for the extraction of pharmaceutics: outcomes from a 3 year collaborative industry/academia research programme.

Journal of chromatography. A·2013

Search research articles

Related Experiment Video

Updated: May 21, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Immunotherapy for primary immunodeficiency diseases.

¹Department of Clinical Immunology, St James's University Hospital, Beckett Wing, Leeds, Yorkshire LS9 7TF, UK. philipwood1@nhs.net

The Medical Clinics of North America

|June 19, 2012

Summary

Antibody deficiency disorders and hereditary angioedema are common in adults. Immunoglobulin therapy improves quality of life, while novel treatments address complications and emerging therapies show promise.

More Related Videos

Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR

Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR

Published on: December 6, 2014

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Related Experiment Videos

Last Updated: May 21, 2026

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Transduction and Expansion of Primary T Cells in Nine Days with Maintenance of Central Memory Phenotype

Published on: March 18, 2020

Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR

Simultaneous Quantification of T-Cell Receptor Excision Circles (TRECs) and K-Deleting Recombination Excision Circles (KRECs) by Real-time PCR

Published on: December 6, 2014

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Novel Protocol for Generating Physiologic Immunogenic Dendritic Cells

Published on: May 17, 2019

Area of Science:

Immunology
Adult Medicine
Clinical Therapeutics

Background:

Antibody deficiency disorders and hereditary angioedema are prevalent primary immunodeficiency syndromes in adult practice.
Immunologic therapies have markedly improved patient management for these conditions.

Purpose of the Study:

To review current immunologic therapies for antibody deficiency disorders and hereditary angioedema.
To discuss emerging treatment strategies and novel agents for managing complications.

Main Methods:

Literature review of primary immunodeficiency syndromes.
Analysis of current and emerging immunologic therapies.
Discussion of treatment outcomes and future directions.

Main Results:

Immunoglobulin therapy significantly enhances the quality of life for patients with primary antibody deficiencies.
Increased survival rates lead to more frequent encounters with disease complications.
Monoclonal antibody therapy and novel targeted agents show promise for managing these complications.

Conclusions:

Current immunotherapies, particularly immunoglobulin, are effective in managing primary immunodeficiency syndromes.
Future therapeutic approaches will likely involve monoclonal antibodies and novel drugs to address complex complications.
Continued research into targeted therapies is crucial for improving long-term patient outcomes.